US 10533056
Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
granted A61KA61K2039/505A61K31/7088
Quick answer
US patent 10533056 (Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics) held by The Regents of the University of California expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 64
- CPC classes
- A61K, A61K2039/505, A61K31/7088, A61K47/6811, A61K47/6817